Non-Hodgkins Lymphoma | CHOP Research Institute

Can CAR T Cells Effectively Treat Blood Cancers With Downregulated CD20 Antigens?

Published on

Dec 15, 2023

Snapshot Science: Options for Patients With Downregulated CD20 Antigens

Researchers gained insight into how some patients develop resistance to CD20-targeted immunotherapies for certain blood cancers and describe how their findings might offer alternative treatment options.

KTE-X19

This study will take the patients white blood cells - T cells - and change them to turn against the cancer.

Hodgkin Lymphoma (NHL) (BIANCA)

This purpose of this study is to determine the efficacy and safety of tisagenlecleucel (also referred to as CTL019, or Kymriah™) in children, adolescents and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

Susan R. Rheingold, MD

Dr. Rheingold's research interests center on acute lymphocytic leukemia, and she serves on the Children's Oncology Group's Relapsed ALL, Infant ALL, and Complementary Therapies committees. In addition, she is investigates complementary and alternative therapies, supportive care for oncology patients undergoing chemotherapy, medical education, and rare childhood tumors.

E-mail:

rheingold [at] chop.edu